Summary
Ludwig Norbert Michel Hantson (born August 1962)[1] is a Belgium businessman, the CEO of Alexion Pharmaceuticals since March 2017. He was the president and CEO of Baxalta, an American biopharmaceutical company, from 2015 to 2016.
Ludwig N. Hantson | |
|---|---|
| Born | Ludwig Norbert Michel Hantson August 1962 (age 61) |
| Nationality | Belgian |
| Alma mater | University of Louvain |
| Title | CEO, Alexion Pharmaceuticals |
Early life edit
Hantson received a PhD in Motor Rehabilitation and Physical Therapy from the University of Louvain in Belgium.[2]
Career edit
Hantson was corporate vice president and president, international of Baxter from May 2010, before becoming CEO of Baxalta from July 2015, when Baxalta was spun off by its parent company, Baxter International until the finalization of Baxalta's acquisition a year later (completed June 2016) by Shire.[2][3]
It was reported in January 2016 that Hantson's exit package, in cash and Shire stock, could be more than $30 million.[4]
In March 2017, Alexion Pharmaceuticals named Hantson as its CEO.[5][6]
In September 2017, Hantson relocated Alexion Pharmaceuticals's headquarters to Massachusetts.[citation needed]
He is a director of Hologic.[7]
References edit
- ^ "Ludwig Norbert Michel HANTSON". Companies House. Retrieved 27 January 2017.
- ^ a b "Executive Profile* Ludwig N. Hantson Ph.D." Bloomberg. Retrieved 5 August 2015.
- ^ "Baxalta CEO to leave after merger with Shire". Chicago Tribune. Retrieved 8 October 2016.
- ^ "Subscription Center". ChicagoBusiness.com. Retrieved 8 October 2016.
- ^ "Appoints". Alexion Pharma. Retrieved 27 March 2017.
- ^ Grover, Natalie (27 March 2017). "Alexion Pharma names former Baxalta chief Ludwig Hantson CEO". Reuters. Retrieved 27 March 2017.
- ^ "Board of Directors Hologic".